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Effect of nodule size on the reliability of fine-needle aspiration biopsy in thyroid nodules
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Background/aim: To investigate the reliability of fine-needle aspiration biopsy (FNAB) in thyroid nodules and benign/malignant
discrimination, particularly in large nodules.
Materials and methods: A retrospective analysis of 1466 nodules in 402 patients with thyroid nodules who underwent thyroid surgery
was made. The pathologic results of the thyroid nodules from preoperative FNAB and postoperative surgical pathology results were
compared.
Results: FNAB was found to be in accordance with the postoperative pathologic results. A concordance between the FNAB and
postoperative pathologic results, particularly in nodules less than 3 cm in size, was detected. However, a similar finding was not detected
in nodules larger than 3 cm in size. The rates, calculated without taking into consideration the nodule dimensions, were found to be:
sensitivity, 47.65%; specificity, 93.98%; false-negative, 52.35%; and false-positive 6.02%
Conclusion: In our experience, the false-negative rate of FNAB in nodules larger than 3 cm was high. Therefore, we have concluded
that in the event of malignant FNAB, this rate is significant; however, in the event of benign FNAB, it should not be trusted too much.
Key words: Thyroid nodules, thyroid cancer, surgery

1. Introduction
Thyroid nodules are commonly detected in the general
population, with an incidence of 17% to 67% found
in adults during ultrasonography. The incidence of
thyroid cancer is generally low. It was shown that thyroid
carcinoma frequency is higher in large thyroid nodes.
Fine-needle aspiration biopsy (FNAB) is the gold standard
initial step for the evaluation of thyroid nodules and has
significantly reduced the number of surgeries performed
unnecessarily for diagnostic purposes (1,2). Unfortunately,
FNAB cytology seems to have a high false-negative rate in
large nodules.
2. Materials and methods
In this study, the FNAB pathology results and the
postoperative pathology results of patients who underwent
thyroidectomy due to a nodular goiter were compared and,
additionally, we investigated whether the dimension of the
thyroid nodule had an impact on the FNAB results.
This study was performed retrospectively by evaluating
the records of patients who underwent thyroidectomy due
to nodular goiter in the Second Department of General
* Correspondence: sametyalcin71@yahoo.com
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Surgery of the Ankara Training and Research Hospital of
the Ministry of Health between July 2006 and August 2008.
Overall, 487 patients who underwent thyroidectomy
with the diagnosis of nodular goiter were evaluated.
Of those, 402 patients whose age, sex, symptoms,
physical examination findings, and ultrasonography,
free triiodothyronine (T3), free thyroxine (T4), total T3,
total T4, and thyroid-stimulating hormone (TSH) results
were available and who had had a FNAB procedure
were included. Eighty-five patients with cystic nodules,
who had previously had a thyroidectomy and a relapsed
thyroidectomy, were excluded from the study.
Serum T3, T4, and TSH levels were checked in all patients
included in the study, and all patients underwent thyroid
ultrasonography and ultrasound-guided FNAB. Nodule
dimensions, number of nodules, FNAB pathology results,
and postoperative pathology outcomes were recorded
according to the results of thyroid ultrasonography.
All euthyroid patients and those with hypothyroidism
who were included in the study underwent ultrasoundguided FNAB. Patients who had toxic and/or had
laboratorial hyperthyroidism underwent the same
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procedure after becoming euthyroid following medical
antithyroid treatment. The results of the FNAB
pathology were divided into 4 groups as malignant,
benign, suspicious, and insufficient material in terms of
malignancy. The FNAB procedure was repeated in patients
whose pathology results were found to be insufficient. The
pathology reports in which malignancy was suspected and
those that were reported as insufficient material again after
the third repeat were included in the malignant group. The
results of these 4 groups were collected into 2 groups as
benign and malignant to be used in statistical analysis in
this study.
Hurthle cell carcinoma, medullar carcinoma, follicular
carcinoma, papillary carcinoma, and undifferentiated thyroid
carcinoma were considered as malignant thyroid diseases.
Remaining diseases, reported as Hurthle cell adenomas,
diffuse hyperplasia, follicular adenoma, granulomatous
thyroiditis, Hashimoto’s thyroiditis, lymphocytic thyroiditis,
nodular hyperplasia, nodular colloidal goiter, and Riedel
thyroiditis, were grouped as benign.
Statistical analysis in this study was performed
based on the data collected, including FNAB pathology
results, postoperative pathology outcomes, and nodule
dimensions.
2.1. Statistical analysis
The SPSS (SPSS Inc., Chicago, IL, USA), was used in the
statistical analysis. In addition to the descriptive statistical
methods (mean, standard deviation), Student’s t-test was
used for comparison of the descriptive data with normal
distribution when the study data were evaluated. For
comparison of the qualitative data, chi-square, McNemar,
and kappa goodness-of-fit tests were used. Results were

evaluated at the 95% confidence interval and the P < 0.05
significance level.
3. Results
A total of 1466 nodules were identified in patients by
ultrasonography. Of the patients, 313 (77.86%) were
female and 89 (22.14%) were male. Mean patient age was
47.67 ± 12.82 years (range: 17–79). Median patient age
was 47 years. The women’s ages ranged between 17 and 79,
with a mean age of 46.96 ± 12.89 and a median of 46. The
men’s ages ranged between 19 and 75; their mean age was
50.18 ± 13.30 and the median was 50. The female-to-male
ratio was found to be 3.52:1.
In terms of the distribution of nodules by sex, the
number of nodules was 1139 (77.70%) in female patients
and 327 (22.30%) in male patients (Table 1).
Regarding nodule dimensions measured according to
ultrasonography, the smallest nodule was measured as 2
mm in size and the largest nodule size was 100 mm. When
we classified nodules according to their sizes as 0 to 9 mm,
10 to 19 mm, 20 to 29 mm, 30 to 39 mm, and larger than 40
mm, the majority of the nodules (39.56%) were found to
be in the small nodule group of 0–9 mm. There were also
patients with more than 1 nodule.
According to the results of FNAB, the patients were
grouped into 4 groups as benign, malignant, suspicious,
and insufficient material in terms of malignancy,
respectively. The ultrasound-guided FNAB procedure was
repeated if insufficient material was reported. Nodules
were grouped as malignant or benign according to the
final results. Distribution of the nodules according to the
results of FNAB is shown in Table 2.

Table 1. The distribution of patients and nodules by sex.
Male

Female

Total

Patients

89

22.14%

313

77.86%

402

Number of nodules

327

22.30%

1139

77.70%

1466

Table 2. Distribution of the FNAB results to the number of nodules as benign/malignant.
FNAB by the number
of nodules

Male

Female

Total

n

%

n

%

n

%

Benign

71

24.07

224

75.93

295

73.38

Malignant

5

13.51

32

86.49

37

9.20

Suspicious

6

12.50

42

87.50

48

11.94

Insufficient

7

31.82

15

68.18

22

5.47

Total

89

22.14

313

77.86

402

100

1003
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In the postoperative pathologic evaluation, 103
(25.62%) patients were reported as malignant and 299
(74.38%) as benign cases (Table 3).
Similarly, the postoperative pathology results were
reviewed on the basis of nodules, and 170 (11.60%) nodules
were reported as malignant and 1296 (88.40%) as benign
(Table 4). According to our results, distributions of the
postoperative pathology results by sex did not significantly
differ (chi-square, P > 0.05). When the nodule dimensions
were taken into account from the postoperative pathology
results (Table 5), the number of malignant nodules was
found to be higher in the group including 10–19 mm
lesions, although the number of benign nodules was
higher in the group of 0 to 9 mm.
From the pathology results and nodule dimensions
it was seen that the larger the nodule dimension was,
the higher the rate of malignancy was (Table 5). The

malignancy rate, which was 11.60% in total, reached up to
19.57% in the 30–39 mm nodule size group. A significant
difference between malignancy rates among the groups
was detected (Table 5) (chi-square, P < 0.05). Thereafter,
the nodules were grouped into 2 groups, as less than
30 mm in size and larger than 30 mm in size, and the
malignancy rate was found to be increased in the group
with thyroid nodules of >30 mm (Table 6). This difference
was statistically significant (chi-square, P < 0.05).
In Cohen’s kappa analysis performed between the
results of FNAB and the postoperative pathology, while the
kappa coefficient (κ) value of the group below 30 mm was
0.50, the κ value in the group above 30 mm was calculated
as 0.16.
According to the kappa analysis, the values are
considered as follows: 0 to 0.20, very weak; 0.21 to 0.40,
weak; 0.41 to 0.60, moderate; 0.61 to 0.80, good; and 0.81

Table 3. Distribution of the postoperative pathology results to sex by the number of patients.
FNAB by the number
of patients

Male

Female

Total

n

%

n

%

n

%

Benign

69

77.53

230

73.48

299

74.38

Malignant

20

22.47

83

26.52

103

25.62

Total

89

22.14

313

77.86

402

100

Table 4. Distribution of the postoperative pathology results to sex by the number of nodules.

By the number of nodules

Male

Female

Total

n

%

n

%

n

%

Benign

288

88.07

1008

88.50

1296

88.40

Malignant

39

11.93

131

11.50

170

11.60

Total

327

1139

1466

Table 5. Distribution of the postoperative pathology results by nodule dimension.

Dimension

1004

Benign

Malignant

Total

n

%

n

%

n

1 to 9 mm

536

92.41

44

7.59

580

10 to 19 mm

401

87.94

55

12.06

456

20 to 29 mm

172

86.43

27

13.57

199

30 to 39 mm

74

80.43

18

19.57

92

>40 mm

113

81.29

26

18.71

139

Total

1296

88.40

170

11.60

1466
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Table 6. Postoperative pathology results in the groups of 0 to 29 mm and above 30 mm.
Benign

Dimensions

Malignant

Total

n

%

n

%

n

1 to 29 mm

1109

89.80

126

10.20

1235

>30 mm

187

80.95

44

19.05

231

Total

1296

88.40

170

11.60

1466

to 1.00, excellent. Accordingly, while the concordance in
the group above 30 mm is very poor, this value is moderate
in the group below 30 mm.
When we grouped nodules as below 30 mm and above
30 mm in size and examined their postoperative pathologic
distributions, the rate of benign nodules was 89.80% (1109
nodules) and the rate of malignant nodules was 10.20%
(126 nodules) in the group of nodules smaller than 30
mm in size (Table 6), while the rate of benign nodules was
80.95% (187 nodules) and the rate of malignant nodules
was 19.05% (44 nodules) in the group of nodules larger
than 30 mm in size. There was a statistical difference
between these 2 groups (chi-square test, P < 0.05).
In order to judge the capability and performance
of these diagnostic tests, a control test must be carried
out by a proven method and the results compared. This
control was performed by a McNemar statistical test, and
if the diagnostic test results were found to be identical

to the results of the actual diagnosis, then the validity
of the diagnostic test was approved (1). For this reason,
the McNemar test, performed for the results between
the FNAB and the postoperative pathology, showed that
the FNAB was in concordance with the postoperative
pathology (P < 0.05). The rates, calculated without taking
into consideration the nodule dimensions, were found
as sensitivity, 47.65%; specificity, 93.98%; false-negative,
52.35%; and false-positive, 6.02%. However, significant
changes in nodules of below 30 mm and above 30 mm
were observed in the evaluation performed based on the
nodule dimension (Table 7).
The results obtained when nodules were grouped as
above 30 mm and below 30 mm in dimension are shown
in Table 8. There is a statistically significant difference
between the results obtained from the group below 30 mm
and the results obtained from the group above 30 mm in
size (chi-square, P < 0.05).

Table 7. Sensitivity, specificity, false-negative, and false-positive rates of the tests by nodule dimensions.
Dimensions (mm)

0–9

10–19

20–29

30–39

>40

All

Sensitivity

61.36%

56.36%

48.15%

22.22%

23.08%

47.65%

Specificity

96.08%

93.52%

91.28%

91.89%

91.15%

93.98%

False-negative

38.64%

43.64%

51.85%

77.78%

76.92%

52.35%

False-positive

3.92%

6.48%

8.72%

8.11%

8.85%

6.02%

Table 8. Sensitivity, specificity, false-negative, and false-positive rates of nodule
dimensions below and above 30 mm.
<30 mm

>30 mm

All

Sensitivity

56.35%

22.73%

47.65%

Specificity

94.41%

91.44%

93.98%

False-negative

43.65%

77.27%

52.35%

False-positive

5.59%

8.56%

6.02%
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4. Discussion
Thyroid nodules are a common clinical problem. In
epidemiological studies palpable thyroid nodules were
detected in approximately 5% of women and in 1% of men
in regions where enough iodine could be taken up. On the
other hand, thyroid nodules were detected in 19% to 67% of
randomly selected individuals (more often in women and
elderly people) by high-resolution ultrasonography (2). In
studies carried out in Turkey, this rate has been reported
as higher than 2.8% (3). In autopsy series, thyroid nodules
were detected in 35%–50% of thyroid glands, and it was
possible to detect small nodules in most of the glands that
were found normal in palpation (4–6). Ultrasound helps
to demonstrate the prevalence of nodular goiters (4–6).
Although nodular thyroid diseases are relatively
common, thyroid cancers are relatively rare and account
for less than 1% of all malignant neoplasm. Between 3%
and 5% of thyroid nodules are malignant (7–9). When a
nodule is detected in the thyroid gland, it is important to
differentiate between benign and malignant nodules with
FNAB, as that will have an impact on the type of surgical
approach. However, it is also important not to waste time
or perform unnecessary investigations. Although medical
history, age, sex, radiation history, and family history
are helpful in evaluating nodules, they are not certainly
diagnostic. However, approximately 6% of the patients
treated with radiotherapy for upper chest and neck diseases
at an age of younger than 5 years carry an increased risk of
developing carcinomas (7).
While the annual incidence was 3.6/1000 in 1973, this
rate reached 8.7/1000 in 2002, an increase of 2.4 times
(for increase trend, P < 0.001). This increase trend is
continuous. Almost all of this increase can be attributed to
papillary thyroid cancer, whose incidence almost increased
2.9 times between 1988 and 2002. Moreover, 49% of this
increase is due to cancers of 1 cm or smaller in size and
87% is due to cancers of 2 cm or smaller in size. The change
in tumor dimensions may be due to the increase in the use
of neck ultrasonography, early diagnosis and treatment,
and changes in initial treatment and follow-up trends in
many patients (2).
There are no precise criteria for differentiating
malignant and benign thyroid nodules ultrasonographically
or scintigraphically. The criteria for diagnosing
malignancy in ultrasonography includes the presence of
microcalcification, solid or predominantly solid internal
structure, irregular contour, hypoechoic internal structure,
and larger front and rear diameter than transverse diameter
(10). The presence of lymphadenopathy and adjacent
organ invasion are findings with a high specificity for
malignancy. The number of nodules, nodule dimensions,
and growth rate interval are nonspecific features for thyroid
malignancies (10). The most specific ultrasonography
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finding for thyroid malignancies is microcalcification. It is
observed in 29% to 59% of primary thyroid carcinomas
and especially in papillary thyroid carcinomas (11–13).
However, small anechoic cystic nodules, smaller than 4 cm
in size, which include microparticles and do not contain a
solid structure, usually with regular edges of the regular
and thin hypoechoic halo around it, are considered as
benign. Therefore, FNABs of thyroid nodules guided by
ultrasonography, scintigraphy, and physical examination
along with cytological evaluation of the materials have
become standard diagnostic tools in the diagnosis of these
lesions (14,15).
FNAB is the most convenient and economical method
for the evaluation of thyroid nodules. Retrospective studies
revealed that the rates for both false-negative results
and failure to diagnose in ultrasound-guided FNABs
performed with ultrasonography are much lower when
compared to palpation. For this reason, ultrasound-guided
FNAB should be preferred in thyroid nodules with a high
nondiagnostic cytology (cystic component of >25%–50%)
or with a high probability of sampling error (difficult to
palpate or posterior nodules) (Table 3). If ultrasonography
confirms the presence of a nodule in a palpated region,
FNAB can be conducted, accompanied by palpation or
ultrasound-guided. The results of FNAB are divided into 4
categories as follows; nondiagnostic, malignant (with 95%
probability of malignancy after surgery), indeterminate
or neoplasia suspected, and benign. To these categories
were added 2 more categories at the latest National Cancer
Institute Thyroid Fine-Needle Aspiration State of the
Science Conference: follicular neoplasm with unidentified
malignancy suspicion (50% to 75% risk of malignancy) and
importance (5% to 10% risk of malignancy). In addition,
at the conference both follicular and Hurtle cell neoplasms
were proposed to be identified as ‘uncertain’ (15%–25%
risk of malignancy) (2).
Patients with multiple thyroid nodules are also at
risk of malignancy, as much as patients with solitary
nodules. Despite the risk of malignancy being the same
in each patient regardless of nodule number, there is a
larger study that reports that the risk of solitary nodules
for malignancy is higher than nonsolitary nodules.
The performance of ultrasonography is required to
identify the nodules. However, if only the ‘biggest’ or
‘dominant’ nodule is aspirated, a thyroid cancer can
remain undetected. Radionuclide examination should be
considered in patients with low or low–normal ranges of
serum TSH. Patients diagnosed as hypofunctional after
such an examination should have FNAB performed (2).
The main problem, when thyroid nodules are detected is
to make a benign/malignant differentiation of nodules. The
most valuable method for benign/malignant differentiation
of thyroid nodules is FNAB (16). The presence of sufficient
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sampling and an experienced cytopathologist are 2 major
factors for the success of FNAB (11). It is reported that
false-negative and false-positive rates must be used instead
of sensitivity and specificity rates for evaluating the success
of FNAB. Some researchers found the false-negative rate of
FNAB as 0%–1% and false-positive rate as less than 5% (17).
Furthermore, 99% of nodules diagnosed benign as a result
of FNAB have been shown to remain benign for 10 years
(18). However, imaging of the thyroid gland periodically is
recommended due to the adjacent nodules in the thyroid
that did not have FNAB applied (19). Situations that require
reevaluation in the follow-up are nodule shape change,
growth in dimension, and development of new nodules.
The follow-up interval must be a minimum of 6 months and
a maximum of 18 months (20).
It is well understood that larger thyroid nodules have
a higher risk of cancer (21–27). In the guidelines issued
by the American Thyroid Disease Society in November
2009 it was said that thyroid nodules reported as benign,
especially those above 4 cm in size, require follow-up due
to the possibility of a false-negative rate (5%) that cannot
be ignored (2).
In a study conducted by Hamming et al., the malignancy
rate was found as 27% in a group of patients with solitary
nodules, in which the longest diameter of the dominant
nodule in the multinodular goiter was a minimum of 40
mm and the solid component of the nodule was 75% and
above (14,15,28).
In 1995, Meko and Norton (22) reported that nodules
larger than 3 cm and solid/cystic lesions had a higher
rate of cancer compared to those smaller than 3 cm and
solid nodules. This finding led to the proposal of clinical
diagnostic lobectomy for nodules larger than 3 cm. The rate
of malignancy in nodules larger than 3 cm was found as
19% in our study. When we grouped the thyroid nodules by
their dimensions, similar to the study conducted by Meko
and Norton, there was a statistically significant difference
between the malignancy rate in the group with nodules of
30 mm and above and the malignancy rate in the group
with nodules of below 30 mm (chi-square, P < 0.05) (Table
6). In addition, there was also a statistically significant
difference between the false-negative rate of nodules above
3 cm (77.27%) and the calculated false-negative rates of
nodules below 3 cm (43.65%) in our study (chi-square, P
< 0.05). In addition, while we found the kappa coefficient
as 0.50 between FNAB and postoperative pathology in
the nodule group smaller than 3 cm during the statistical
evaluations, this value in the group with nodules larger
than 3 cm was found as 0.19, which could be regarded as
incongruous. This supports our initial thesis.
Meko and Norton evaluated the characteristics of
thyroid nodules associated with false-negative cytology
in a series of 90 patients. The false-negative FNAB rate in

30 patients with lesions above 3 cm was 5 in their study
(false-negative rate: 16.67%). On the other hand, the falsenegative rate in patients with lesions below 3 cm was 0%.
One of the 5 patients with a false-negative FNAB result
had multiple micropapillary carcinoma foci detected
outside the lesions assessed by FNAB, and another patient
had a cancer of larger than 3 cm outside the nodule of 1 cm
(22). The sample size was larger in our study, and the case
as to whether the presence of thyroid cancer was inside
or outside a malignancy or mass of 3 cm or larger could
not be specifically examined and evaluated. However, the
rate of malignancy of 19.05% in nodules above 3 cm in our
study confirms the high cancer rate found by Meko and
Norton for large thyroid nodules.
The sensitivity of FNAB was reported as ranging from
58.3% to 98% and the specificity of FNAB as ranging from
72% to 100% in the retrospective analysis of 37,895 patients
issued by Ravetto et al. in 2000, and in studies by Cap et al.,
Mandell et al., Sankhla et al., and Bennedbaek et al. (22–
26). The calculations in the majority of these publications
were performed by excluding suspicious lesions from
the studies. In our study, the cases reported as suspicious
lesions after FNAB were analyzed in positive FNAB results.
One of the reasons for this is that we perform surgeries
on patients with suspicious lesions identified by FNAB
in accordance with the principles of oncologic surgery,
and the other reason is that the definitive pathologies of
suspicious lesions are shown to be malignant in between
20% and 50% of cases in various publications (29,30).
McCoy et al. stated that they do not recommend
FNAB as a routine in patients scheduled to undergo
total thyroidectomy in the first place independently of
cancer diagnosis (31); however, as mentioned above, all
the preoperative tests create adverse effects for patients’
mental state, increase the financial burden, and lead
to loss of time, as well as harming the temporary wellbeing of patients and damaging their trust in health care
professionals. Therefore, when we evaluate suspicious
and benign FNAB results in patients with nodules above
3 cm in size, we think that it would be appropriate to
follow-up at more frequent intervals, and even to strongly
advise surgery, for patients with malignant findings, such
as receiving radiation to the head and neck in childhood
or whole-body irradiation history for bone marrow
transplantation, the presence of thyroid cancer or thyroid
cancer syndrome in first-degree relatives (Cowden’s
syndrome, familial polyposis, Carney complex, multiple
endocrine neoplasia type 2, Werner syndrome, etc.),
exposure to ionizing radiation fall-out in childhood and
adolescent periods, rapid growth of the lesion, hoarseness,
vocal cord paralysis, lateral cervical lymphadenopathy,
invasion of the nodule to surrounding regions and
hypoechoic nodules in ultrasonography according to the
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normal thyroid parenchyma, increase in internal nodule
vascularity, irregular infiltrative borders, presence of
microcalcifications, absence of halo, and higher nodule
height than transverse size suggestive of malignancy, which
was also specified in the guidelines issued by the American
Thyroid Disease Society in November 2009. False-negative
FNAB results may be secondary to the problems of
sampling, processing, scanning, interpretation, or clinical
correlation. A false-negative result can significantly delay
the appropriate surgical treatment in patients with thyroid
cancer. Therefore, we think that the assessment of FNABs
by expert cytopathologists is important.
Follicular lesions typically appear to be follicular
epithelial cells that create microfollicles with a minimal
colloid floor in FNAB, and they are the cause of about 20%
of nodule biopsies. Screening of malignancy in follicular
lesions is usually not possible only on the basis of cytology;
it requires diagnostic lobectomy (23).
It is understood that what is ultimately important is
the overlooked cancer rate rather than any overlooked
follicular lesions, but the malignant potential of follicular
adenomas is not clear. However, the situation whereby 8 of
9 cancer cases (88.9%) overlooked in the study performed
by McCoy et al. were follicular pattern neoplasms reveals
that this group of lesions causes a false-negative cytology
rate in terms of cancer. This situation is perhaps not
surprising because moderately large follicular cell-lined
structures filled with colloid, such as large follicular variant
papillary thyroid cancers, follicular carcinomas, and
follicular adenomas, can display significant intratumoral
heterogeneity or cystic degeneration, and this makes
sampling for a follicular lesion or malignancy diagnosis
difficult (31).
In our study, the sensitivity of FNAB was calculated
as 47.65% and the specificity as 93.98% when the nodule
dimensions were not taken into account. However, when
the nodule dimensions were taken into account, while the
sensitivity for dimensions of less than 30 mm increased
to 56.35%, the specificity increased to 94.41%, a value
consistent with the literature. The sensitivity with nodules
above 30 mm decreased to 22.73% and the specificity to

91.44%. The conclusion to be drawn here is that sufficient
cytological samples must be obtained by performing
FNAB more carefully, samples must be delivered to the
pathology laboratory as soon as possible in an appropriate
manner, and, most importantly, cytological samples must
be examined by expert and experienced cytopathologists
and the false-negative rate in suspicious lesions must be
reduced to the acceptable limits defined in the literature.
The false-positive rate is reported as 1% to 8% in
several publications (32–38). This rate in our study was
found as 6.02%, taking all the patients into account, and in
the patients with nodules above 3 cm in size it was found
as 8.56%. These rates are consistent with the rates in the
literature.
We agree with the recommendations in the study
performed by McCoy et al. (31). Molecular tests can
provide additional guidance in the evaluation of benign
or large thyroid nodules with indeterminate cytology as
their clinical roles continue. For example, the presence of
BRAF, RET, RAS, and PAX8-PPAR gamma mutations may
allow further characterization of FNAB cytology samples
(39,40). The patient subgroup with large thyroid nodules or
benign or indeterminate cytology can benefit potentially
from molecular analysis as these analyses become more
widespread and guidelines are developed from evidencebased data.
In conclusion, the incidence of cancer is high in thyroid
nodules of 3 cm or larger (19.05%). Benign FNAB cytology of
large thyroid nodules has a false-negative rate unacceptably
high in terms of overlooked follicular lesions (77.21%).
FNAB may be useful in larger lesions, especially if the
cytology is malignant, because it can provide opportunity
for preoperative counseling. However, it should not change
the decision to progress to surgery for a thyroid nodule of 3
cm or larger as a result of a benign FNAB.
New prospective studies should be carried out on this
subject in order to help us gather more reliable information.
After new studies, we predict that nodule dimension will
be accepted as a criterion for performing FNAB, and the
decision for surgery for nodules above an estimation value
can be taken directly.
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